肝硬化患者的电生理学参数
Dragoş Lupu1, Cristian Stănescu, Dănuţ Laurenţiu Nedelcu
1Department of Pediatric Surgery and Orthopedics, Faculty of Medicine, University of Medicine and Pharmacy of Craiova, Romania; alin.stoica76@gmail.com.
概括
肝硬化患者表现出显著的自主功能障碍,其证据是心率变化减少. 然而,这项研究发现,与健康对照人群相比,肝硬化患者中没有显著的QT间隔异常.
科学领域:
- 心脏病学 心脏病学
- 胃肠病学 胃肠病学
- 电子生理学 电子生理学
背景情况:
- 肝硬化与各种电生理学异常有关.
- 在肝硬化患者中,QT延长和自主功能障碍很普遍.
研究的目的:
- 为了评估肝硬化患者的电生理异常.
- 为了将这些异常与健康个体进行比较.
主要方法:
- 60名肝硬化患者和50名对照患者接受了心电图,瓦萨尔瓦机动,24小时霍尔特监测和压力测试.
- 评估的参数包括瓦萨尔瓦指数,心率 (HR),校正的QT (QTc) 间隔和正常至正常 (NN) 间隔的标准偏差 (SDNN).
主要成果:
- 肝硬化患者的瓦萨尔瓦指数降低,SDNN值显著降低,表明自主功能障碍.
- 两组之间休息HR或QTc间隔没有发现统计学上显著的差异.
- 肝硬化患者在运动后显示显著更高的HR值.
结论:
- 与健康个体相比,肝硬化患者的自主功能障碍增加.
- 在肝硬化患者中没有发现显著的QT间隔异常.
相关概念视频
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
382
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
382
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
271
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
271
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
379
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
379
Cirrhosis I: Introduction
28
Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...
28
Cirrhosis II: Pathophysiology
42
Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to...
42
Hepatic Encephalopathy
53
DefinitionHepatic encephalopathy is a reversible neurologic syndrome that results from advanced liver dysfunction or portosystemic shunting. It leads to disturbances in cognition, behavior, and motor function due to the brain’s exposure to gut-derived toxins that the liver fails to detoxify.EtiologyThis condition develops either in the setting of acute fulminant hepatitis or progressively during chronic liver disease, such as cirrhosis and portal hypertension. Portosystemic...
53


